HC Wainwright Brokers Raise Earnings Estimates for PDSB

PDS Biotechnology Corporation (NASDAQ:PDSB) – Research analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for PDS Biotechnology in a research report issued on Wednesday, May 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.14) per share for the quarter, up from their prior estimate of ($0.17). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at ($0.61) EPS and FY2028 earnings at ($0.49) EPS.

Other equities analysts have also issued research reports about the company. Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Stock Performance

NASDAQ:PDSB opened at $1.18 on Tuesday. The firm has a market capitalization of $65.87 million, a PE ratio of -1.76 and a beta of 1.51. The business’s fifty day moving average price is $0.92 and its 200 day moving average price is $0.87. The company has a debt-to-equity ratio of 2.73, a current ratio of 2.26 and a quick ratio of 2.26. PDS Biotechnology has a 12 month low of $0.51 and a 12 month high of $1.92.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02.

Hedge Funds Weigh In On PDS Biotechnology

Several large investors have recently bought and sold shares of the business. Susquehanna International Group LLP boosted its stake in PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after acquiring an additional 80,937 shares in the last quarter. Squarepoint Ops LLC boosted its stake in PDS Biotechnology by 116.1% in the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after acquiring an additional 156,662 shares in the last quarter. Renaissance Technologies LLC boosted its stake in PDS Biotechnology by 25.0% in the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after acquiring an additional 44,100 shares in the last quarter. Virtu Financial LLC acquired a new position in PDS Biotechnology in the fourth quarter valued at $25,000. Finally, Marshall Wace LLP acquired a new position in PDS Biotechnology in the second quarter valued at $91,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.